Select Language
FGF basic
FGF basic Overview
| English Name | Fibroblast growth factor 2 | Approved Drugs | 1 |
| Drugs in Clinical Trials | 4 | Target Synonym | FGF-2，Heparin-binding growth factor 2，Basic fibroblast growth factor，FGFB，bFGF，HBGF-2，FGF2，Fibroblast Growth Factor 2 (Basic)，Basic Fibroblast Growth Factor BFGF，Prostatropin，Fibroblast Growth Factor 2 |
| Highest Development Stage | Approved | ||
| English Name | Fibroblast growth factor 2 |
| Target Synonym | FGF-2，Heparin-binding growth factor 2，Basic fibroblast growth factor，FGFB，bFGF，HBGF-2，FGF2，Fibroblast Growth Factor 2 (Basic)，Basic Fibroblast Growth Factor BFGF，Prostatropin，Fibroblast Growth Factor 2 |
| Approved Drugs | 1 |
| Drugs in Clinical Trials | 4 |
| Highest Development Stage | Approved |
FGF basic Product List
- Product Category
Protein (7)Kits (1)
- Product Status
Launched (8)
- Species
Human (8)
- Tag
Tag Free (6)His Tag & Avi Tag (1)- (1)
- Conjugate
Unconjugated (6)Biotin-labeled (1)- (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature | Order Now |
|---|---|---|---|---|---|---|---|
HOT BFF-H4117 |  Human | E. coli | Human FGF basic Protein, premium grade |  |  |  |  Add to Cart |
HOT BFF-H5115 | Human | E. coli | Human FGF basic (154aa) Protein, premium grade |  | | | Add to Cart |
HOT GMP-FGCH17 | Human | E. coli | GMP Human FGF basic Protein |  | | | Add to Cart |
BFF-H4118 | Human | E. coli | Human FGF basic Protein, Research Grade |  | |  | Add to Cart |
BFF-H5113 | Human | E. coli | Human FGF basic Superior Stable Mutant Protein, premium grade | | | Add to Cart | |
BFF-H5114 | Human | E. coli | Human FGF basic Superior Stable Mutant Protein, Research Grade | | | Add to Cart | |
CEA-C082 | Human | - | Human bFGF/FGF2 ELISA Kit | Add to Cart | |||
FGC-H81E3 | Human | E. coli | Biotinylated Human FGF basic Protein, Avitag™,His Tag (HPLC verified) |  | | | Add to Cart |
Total: 8
- 1
FGF basic Background
FGF basic is a member of the FGF family of at least 23 related mitogenic proteins which show 35-60% amino acid conservation. FGF acidic and basic, unlike the other members of the family, lack signal peptides and are apparently secreted by mechanisms other than the classical protein secretion pathway. FGF basic has been isolated from a number of sources, including neural tissue, pituitary, adrenal cortex, corpus luteum, and placenta. This factor contains four cysteine residues, but reduced FGF basic retains full biological activity, indicating that disulfide bonds are not required for this activity. bFGF is a critical component of human embryonic stem cell culture medium; the growth factor is necessary for the cells to remain in an undifferentiated state, although the mechanisms by which it does this are poorly defined. It has been demonstrated to induce gremlin expression which in turn is known to inhibit the induction of differentiation by bone morphogenetic proteins. It is necessary in mouse-feeder cell dependent culture systems, as well as in feeder and serum-free culture systems.
FGF basic Synonyms
FGF2,BFGF,FGFB,FGF basic,HBGF-2
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Muparfostat sodium | PI-88 | Phase 3 Clinical | Australian National University | Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Liver Neoplasms; Lung Neoplasms; Melanoma; Neoplasms; Prostatic Neoplasms; Skin Melanoma; Solid tumours | Details |
| RBM-007 | ID3 (21); APT-F2; RBM-007 | Phase 2 Clinical | Ribomic | Achondroplasia; Macular Degeneration | Details |
| Fibroblast growth factor 2 gene therapy (ID Pharma) | SeV-10101; SEV-10101; DVC-10101; BF-30 | Phase 2 Clinical | Dnavec | Arterial Occlusive Diseases; Intermittent Claudication; Ischemia; Peripheral Arterial Disease; Peripheral arterial occlusive disorders | Details |
| Recombinant Human Epidermal Growth Factor Derivative Gel (Uni-Bio Science) | Phase 1 Clinical | Uni-Bio Science Group | Wounds and Injuries | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Thalidomide | NSC-66847; NSC-527179; K-17; FPF-300; FPF300 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Mainland China | Leprosy, Lepromatous; Multiple Myeloma | Changzhou Pharmaceutical Factory | 1982-01-01 | Acquired Immunodeficiency Syndrome; Adenocarcinoma, Clear Cell; Adenoma, Islet Cell; Amyotrophic Lateral Sclerosis; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Anemia, Sideroblastic; Angiodysplasia; Appendiceal Neoplasms; Arachnoiditis; Arteriovenous Malformations; Axial Spondyloarthritis; beta-Thalassemia; Burning Mouth Syndrome; Carcinoid Tumor; Carcinoma, Adenosquamous; Carcinoma, Hepatocellular; Cholangitis, Sclerosing; Colorectal Neoplasms; Cough; Endometrial Neoplasms; Endometriosis; Epilepsy; Erythema Nodosum; Gastric Antral Vascular Ectasia; Gastrointestinal Hemorrhage; Genetic Diseases, Inborn; Glioma; Graft vs Host Disease; Head and Neck Neoplasms; Hemoglobinopathies; HIV Infections; HIV Wasting Syndrome; Hodgkin Disease; Hormone-Resistant Prostate Neoplasms; Hypertension, Portal; Idiopathic Pulmonary Fibrosis; Kidney Neoplasms; Leiomyosarcoma; Leprosy, Lepromatous; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myelomonocytic, Chronic; Liver Neoplasms; Lung Neoplasms | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to: